Phreesia Inc delivered a solid QQ2 2026 performance, underpinned by ongoing demand for its SaaS-based patient intake and payments platform. Revenue of USD 117.3 million represented a YoY increase of approximately 14.8% and a modest sequential uptick of about 1.1%, with operating income of USD 26.15 million and a double-digit operating margin (~22.3%). EBITDA was positive at USD 6.85 million (EBITDA margin ~5.8%), and net income reached USD 0.654 million with EPS of USD 0.011. The quarter also demonstrated robust cash generation, with operating cash flow of USD 14.84 million and free cash flow of USD 13.07 million. The company ended the period with USD 98.27 million in cash and equivalents and a net debt position of USD -93.51 million, reflecting a strong liquidity profile and limited net leverage.